OFC Infusion + FC infusion
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukaemia, Lymphocytic, Chronic
Conditions
Leukaemia, Lymphocytic, Chronic
Trial Timeline
Mar 12, 2009 → Oct 25, 2017
NCT ID
NCT00824265About OFC Infusion + FC infusion
OFC Infusion + FC infusion is a phase 3 stage product being developed by Novartis for Leukaemia, Lymphocytic, Chronic. The current trial status is completed. This product is registered under clinical trial identifier NCT00824265. Target conditions include Leukaemia, Lymphocytic, Chronic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00824265 | Phase 3 | Completed |
Competing Products
20 competing products in Leukaemia, Lymphocytic, Chronic